bioAffinity Technologies, Inc. — Form 8-K
Filed November 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
bioAffinity Technologies amended its Certificate of Incorporation effective November 20, 2026, increasing authorized common stock to 200,000,000 shares at $0.007 par value and authorized preferred stock to 20,000,000 shares at $0.001 par value. The amendment was approved by the board and stockholders at a duly convened meeting. No specific details provided on prior authorized share counts or intended use of increased authorization.
Why this rating
Share authorization increase is routine capital structure housekeeping, common for small-cap biotech. No immediate dilution stated; authorization alone does not change ownership. Moderate flag only because details on prior cap table and intended financing purpose are absent.
See more from November 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.